Journal
IMMUNOTHERAPY
Volume 9, Issue 12, Pages 979-993Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2017-0062
Keywords
chimeric antigen T cells; hematological malignancy; leukemia; lymphoma; refractory; relapse
Categories
Funding
- National Cancer Institute, National Institutes of Health, Bethesda, MD, USA [P30 CA023074]
- NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as well as safety of CD-19 and CD-20 chimeric antigen receptor-T therapy for B-cell hematologic malignancies. A total of 16 studies with 195 patients were identified. The pooled analysis showed an overall response rate of 61% (118/195) with complete response of 42% (81/195) and partial response of 19% (37/195). Major adverse events were cytokine release syndrome 33%, neurotoxicity 33% and B-cell aplasia 54%. Collectively, the results indicate encouraging response in relapsed/refractory B lymphoma and leukemia, especially in acute lymphoblastic leukemia (ALL) patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available